Nexalin technology announces positive results from clinical study of its gen-2 tacs device for treating adult patients with chronic insomnia

Clinical study demonstrated clinically meaningful and statistically significant improvements in key sleep parameters, compared to adult patients treated with placebo data published in journal of psychiatric research suggests that the gen-2 tacs device may have the potential to reduce chronic insomnia and consistently improve sleep quality and efficiency in adults chronic insomnia is often associated with fatigue, mood changes, difficulty concentrating and impaired daytime functioning houston, texas, march 06, 2024 (globe newswire) -- nexalin technology, inc. (the “company” or “nexalin”) (nasdaq: nxl; nxliw) today announced positive results of a clinical study of its gen-2 tacs device (“tacs”) for the treatment of chronic insomnia. this clinical study, conducted at xuanwu hospital of capital medical university in beijing and beijing anding hospital, evaluated the treatment response of 120 adult participants who were divided into two prespecified age subgroups.
NXL Ratings Summary
NXL Quant Ranking